PTEN and breast carcinoma: In breast cancer, altered expression of miR-221 and miR-222 has been closely linked to drug resistance, with miR-221 promoting doxorubicin resistance through the PTEN/Akt/mTOR signaling pathway, while miR-222 and miR-29a modulate therapeutic resistance by targeting PTEN [85, 86].